The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
News|Articles|December 2, 2003
- Pharmaceutical Technology-12-02-2003
- Volume 27
- Issue 12
Targeted Cationic Liposomes, Technologies, and Developments
Author(s)Anas El-Aneed
The author provides a brief review of tumor-specific and liver-targeted cationic liposomes and the strategies for the development of liposome-ligand complexes.
Advertisement
Articles in this issue
almost 23 years ago
December 2003almost 23 years ago
All Signs Indicate a Strong 2004 for Contract Servicesalmost 23 years ago
Behavior of Uptake of Moisture by Drugs and Excipientsalmost 23 years ago
Sixth Annual International Employment Survey: Staying the Coursealmost 23 years ago
Drug Pricing Concerns Shape Policy Decisions in 2003almost 23 years ago
In the Spotlight--January 2004almost 23 years ago
December 2003Advertisement
Related to this article
Vivek Gupta of Duquesne University explains at AAPS PharmSci 360 why device decisions can't wait and why excipient makers must test beyond drug molecules.
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
France’s 2030 Health Initiative is driving growth in biotechnology, health innovation, biomanufacturing, and digital health.
CPHI Award winner, Pauline van der Wijst-Janssen, PhD, product development manager and global technical lead at DFE Pharma, explains excipient variability and excipients’ role in continuous manufacturing.
Pauline van der Wijst-Janssen, PhD, of DFE Pharma, won the CPHI Pharma Award for Future Leader. In this interview with PharmTech, she provides advice for scientists looking to advance to leadership roles.
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Drug Shortages Average 5+ Years: PharmTech Explained
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
4
ADCs, Degraders, Agonists: 4 Deals CMC Teams Should Track
5